It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ) . Shares have lost about 3.9% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Jazz due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Jazz Pharmaceuticals PLC before we dive into how investors and analysts h ...

Core Insights - Jazz Pharmaceuticals (JAZZ) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.64, exceeding the Zacks Consensus Estimate of $6.62, with a year-over-year earnings increase of 2% [1] - Total revenues for the quarter rose 10% year over year to $1.2 billion, surpassing the Zacks Consensus Estimate of $1.18 billion [1] - The stock price of Jazz increased by 5% in after-market trading following the earnings report [1] Revenue Breakdown - Net product sales increased by 10.5% year over year to $1.13 billion, beating both the Zacks Consensus Estimate and the internal model estimate of $1.11 billion [3] - Royalty revenues from high-sodium oxybate authorized generic (AG) reached approximately $56 million, up 1% year over year, exceeding the Zacks Consensus Estimate of $53 million [3] - Other royalties and contract revenues amounted to about $10 million, reflecting a 28% increase from the previous year [4] Neuroscience Segment Performance - Sales of neuroscience products rose over 8% year over year to $792 million [5] - Combined net product sales for the oxybate business (Xyrem + Xywav) increased by 12% to $503 million, surpassing the Zacks Consensus Estimate of $481 million [5] - Xywav sales grew by 16% to over $465 million, attributed to strong uptake in narcolepsy and idiopathic hypersomnia indications [6] Oncology Segment Performance - Oncology product sales increased by 16% to over $337 million [8] - Sales of chemotherapy drug Rylaze/Enrylaze reached more than $108 million, up nearly 7% year over year, beating the Zacks Consensus Estimate of $106 million [8] - Zepzelca, for small-cell lung cancer, recorded sales over $90 million, up 15% year over year [8] Operating Costs - Adjusted selling, general and administrative expenses (SG&A) rose about 12% year over year to $360.5 million, primarily due to higher compensation-related expenses [11] - Adjusted research and development (R&D) expenses decreased by 14% to $190 million, mainly due to lower clinical program costs [11] Full-Year 2025 Results - For the full year, Jazz reported adjusted EPS of $8.38, down 54% year over year [12] - Total revenues for the year rose 5% year over year to $4.3 billion, including neuroscience and oncology net product sales of $2.9 billion and $1.1 billion, respectively [12] 2026 Guidance - Jazz expects total revenues for 2026 to be in the range of $4.25 billion to $4.50 billion, indicating a 2.5% year-over-year growth at the midpoint [13] - The company anticipates double-digit growth across its combined epilepsy and oncology franchises, while Xywav sales are projected to remain flat or increase by a mid-single-digit percentage [14] - Adjusted SG&A expenses are expected to be between $1.26 billion and $1.32 billion, while adjusted R&D expenses are projected to be in the range of $725 million to $775 million [14]

Core Insights - Jazz Pharmaceuticals reported revenue of $1.2 billion for the quarter ended December 2025, reflecting a year-over-year increase of 10.1% and an EPS of $6.64, slightly up from $6.60 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $1.18 billion by 1.56%, while the EPS also surpassed the consensus estimate of $6.62 by 0.27% [1] Revenue Performance by Segment - Oncology revenue from Vyxeos was $34.73 million, significantly below the estimated $47.69 million, marking a decline of 34.8% year-over-year [4] - Oncology revenue from Defitelio/defibrotide reached $58.87 million, slightly above the estimated $56.26 million, with a year-over-year increase of 2.1% [4] - Neuroscience revenue from Oxybate (Xywav) was $465.45 million, exceeding the estimated $448.99 million, representing a year-over-year growth of 16.1% [4] - Neuroscience revenue from Epidiolex/Epidyolex was $287.12 million, slightly below the estimated $297.23 million, with a year-over-year increase of 4.4% [4] - Neuroscience revenue from Sativex was $1.5 million, significantly lower than the estimated $5.12 million, reflecting a year-over-year decline of 71% [4] - Total Neuroscience revenue, including Oxybate (Xywav & Xyrem), was $503.23 million, surpassing the estimated $481.03 million, with a year-over-year increase of 11.8% [4] - Total Neuroscience revenue amounted to $791.86 million, exceeding the estimated $783.39 million, with a year-over-year growth of 8.4% [4] - Total Oncology revenue was $337.28 million, above the estimated $322.89 million, reflecting a year-over-year increase of 15.6% [4] - Revenue from Rylaze/Enrylaze was $108.16 million, slightly above the estimated $105.81 million, with a year-over-year increase of 6.6% [4] - Revenue from Zepzelca was $90.44 million, exceeding the estimated $84.24 million, marking a year-over-year growth of 15.5% [4] - Net product sales reached $1.13 billion, surpassing the estimated $1.11 billion, with a year-over-year increase of 10.5% [4] - Oncology revenue from Ziihera was $8.54 million, below the estimated $11.91 million [4] Stock Performance - Jazz Pharmaceuticals' shares have returned +4.2% over the past month, contrasting with a -1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Analysts forecast Jazz Pharmaceuticals (JAZZ) to report quarterly earnings of $6.62 per share, reflecting a year-over-year increase of 0.3%, with anticipated revenues of $1.18 billion, an increase of 8.4% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 13% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts project 'Total revenues- Oncology- Vyxeos' to be $47.69 million, a decrease of 10.4% year-over-year [5]. - For 'Total revenues- Oncology- Defitelio/defibrotide', the estimate is $56.26 million, reflecting a decline of 2.4% [5]. - 'Total revenues- Neuroscience- Oxybate- Xywav' is expected to reach $448.99 million, an increase of 12% from the previous year [6]. - 'Total revenues- Neuroscience- Epidiolex/Epidyolex' is projected at $297.23 million, showing an 8.1% increase [6]. - The consensus for 'Total revenues- Neuroscience- Total' is $783.39 million, indicating a year-over-year change of 7.2% [7]. - 'Total revenues- Oncology- Total' is estimated at $322.89 million, reflecting a 10.7% increase [8]. - 'Total revenues- Oncology- Rylaze/Enrylaze' is projected at $105.81 million, suggesting a 4.3% year-over-year change [8]. - 'Total revenues- Oncology- Zepzelca' is expected to be $84.24 million, indicating a 7.6% increase [9]. - 'Revenues- Product sales, net' is anticipated to be $1.11 billion, reflecting an 8.2% increase [9]. - 'Revenues- Royalties and contract revenues' is projected at $63.75 million, indicating a 1.3% increase [9]. Stock Performance - Over the past month, Jazz shares have recorded a return of -0.3%, compared to the Zacks S&P 500 composite's -0.8% change [10]. - Based on its Zacks Rank 3 (Hold), JAZZ is expected to perform in line with the overall market in the upcoming period [10].

Core Insights - Jazz Pharmaceuticals reported strong Q3 2025 earnings, with adjusted EPS of $8.13, surpassing estimates by 24% year over year [2][3] - Total revenues reached $1.13 billion, a 7% increase year over year, also exceeding consensus estimates [2][3] Financial Performance - Net product sales increased nearly 8% year over year to $1.06 billion, beating estimates [3] - Royalty revenues from high-sodium oxybate authorized generic decreased by 9% year over year to $53 million, missing estimates [3] - Neuroscience product sales rose 10% to $774 million, with Xywav sales up 11% to over $431 million [4][5] - Sales of Epidiolex/Epidyolex increased by 20% to about $303 million, driven by volume growth [5] - Oncology product sales rose 1% to about $288 million, with Rylaze/Enrylaze sales at $100 million, also up 1% [7][8] Cost and Guidance - Adjusted SG&A expenses rose 59% year over year to $460 million, primarily due to litigation settlements [11] - Jazz revised its 2025 revenue guidance to $4.18-$4.28 billion, indicating a 3% year-over-year increase at the midpoint [12] - Adjusted EPS guidance was significantly raised to $7.65-$8.45 from the previous $4.80-$5.60 [14] Market Outlook - The consensus estimate for Jazz has shifted upward by 8.54% in the past month, indicating positive investor sentiment [15] - Jazz holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [17] Industry Comparison - Jazz is part of the Zacks Medical - Biomedical and Genetics industry, which has seen Regeneron report a slight revenue increase of 0.9% year over year [19] - Regeneron is expected to post a year-over-year EPS decline of 11.8% for the current quarter, reflecting broader industry challenges [20]

Core Insights - Jazz Pharmaceuticals (JAZZ) reported Q3 2025 adjusted EPS of $8.13, exceeding the Zacks Consensus Estimate of $5.74, primarily due to a $206 million income tax benefit from the Chimerix acquisition, resulting in a 24% year-over-year earnings increase [1][7] - Total revenues increased by 7% year over year to $1.13 billion, surpassing the Zacks Consensus Estimate of $1.10 billion [2][7] - The stock has gained over 11% year to date, compared to the industry growth of 10% [2] Revenue Breakdown - Net product sales rose nearly 8% year over year to $1.06 billion, beating the Zacks Consensus Estimate of $1.04 billion [4] - Royalty revenues from high-sodium oxybate authorized generic (AG) decreased by 9% year over year to $53 million, missing estimates [4] - Other royalties and contract revenues increased by 23% to nearly $9 million [5] Neuroscience Segment Performance - Sales of neuroscience products grew by 10% year over year to $774 million [6] - Combined sales for the oxybate business (Xyrem + Xywav) rose about 5% to $467 million, aligning with Zacks Consensus Estimate [6][8] - Xyrem sales plummeted 39% year over year to nearly $36 million, while Xywav sales increased by 11% to over $431 million [8] Oncology Segment Performance - Oncology product sales rose by 1% to approximately $288 million [10] - Rylaze/Enrylaze sales were $100 million, a 1% increase year over year, but missed estimates [11] - Zepzelca sales were over $79 million, down 8% year over year due to increased competition [12] Operating Costs - Adjusted SG&A expenses rose by 59% year over year to $460 million, primarily due to litigation settlements [14] - Adjusted R&D expenses decreased by 6% to $170 million [14] Financial Guidance - Jazz narrowed its 2025 revenue guidance to $4.18-$4.28 billion, implying a 3% year-over-year increase at the midpoint [15] - Adjusted EPS guidance was raised to $7.65-$8.45, significantly higher than the previous range of $4.80-$5.60 [17]

Core Insights - Jazz Pharmaceuticals reported revenue of $1.13 billion for the quarter ended September 2025, reflecting a 6.7% increase year-over-year and a surprise of +2.16% over the Zacks Consensus Estimate of $1.1 billion [1] - The company's EPS for the quarter was $8.13, significantly higher than the $6.61 reported in the same quarter last year, resulting in an EPS surprise of +41.64% compared to the consensus estimate of $5.74 [1] Revenue Breakdown - Total revenues from Oncology products amounted to $287.84 million, slightly below the average estimate of $291.13 million, with a year-over-year change of +1.1% [4] - Vyxeos generated $37.58 million, which was lower than the $39.17 million average estimate, but showed a year-over-year increase of +9.5% [4] - Defitelio/defibrotide revenues were $51.75 million, down -21.4% year-over-year and below the $56.1 million estimate [4] - Total revenues from Neuroscience products reached $774.43 million, exceeding the $745.62 million estimate, with a year-over-year increase of +10.2% [4] - Oxybate (Xywav) generated $431.41 million, slightly below the $434.72 million estimate, but up +11.1% year-over-year [4] - Epidiolex/Epidyolex revenues were $302.61 million, surpassing the $273.8 million estimate, with a year-over-year increase of +20.3% [4] - Sativex reported revenues of $4.75 million, slightly below the $4.84 million estimate, reflecting a +3.6% year-over-year change [4] - Rylaze/Enrylaze generated $99.87 million, below the $103.76 million estimate, with a year-over-year change of +1.1% [4] - Zepzelca revenues were $79.3 million, lower than the $82.01 million estimate, representing a -7.6% change year-over-year [4] - Net product sales were $1.06 billion, exceeding the $1.04 billion estimate, with a year-over-year increase of +7.6% [4] - Other revenues totaled $2.14 million, below the $3.32 million estimate, reflecting a -3.9% year-over-year change [4] Stock Performance - Jazz Pharmaceuticals' shares returned +0.4% over the past month, underperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Jazz Pharmaceuticals reported a second-quarter 2025 adjusted loss of $8.25 per share, which was wider than the Zacks Consensus Estimate of a loss of $6.12, primarily due to a one-time charge from the acquisition of Chimerix that impacted earnings by $14.75 per share [1][10] Financial Performance - Total revenues increased by 2% year over year to $1.05 billion, aligning with the Zacks Consensus Estimate [2] - Net product sales rose 2% year over year to $986 million, missing the Zacks Consensus Estimate of $999 million and the model estimate of $1 billion [3] - Royalty revenues from high-sodium oxybate authorized generic remained flat year over year at $54 million, exceeding the Zacks Consensus Estimate of $49 million and the model estimate of $43 million [3] - Other royalties and contract revenues increased by 9% year over year to $6 million [4] Neuroscience Segment - Sales of neuroscience products grew by 3% year over year to $707 million [5] - Combined net product sales for the oxybate business (Xyrem + Xywav) rose about 5% to $451 million, surpassing the Zacks Consensus Estimate of $440 million [5] - Xywav sales reached $415 million, up 13%, attributed to strong uptake in narcolepsy and idiopathic hypersomnia indications [6] - Sales of the epilepsy drug Epidiolex/Epidyolex increased by 2% to nearly $252 million, but fell short of the Zacks Consensus Estimate of $271 million [7] Oncology Segment - Oncology product sales decreased by 1% to $274 million [8] - Rylaze/Enrylaze sales were $101 million, down 7% year over year, missing both the Zacks Consensus Estimate and model estimates [9] - Zepzelca sales were $75 million, down 8% year over year, due to increased competition and treatment protocol updates [11] Operating Costs - Adjusted selling, general and administrative expenses rose by 2% year over year to $310 million [13] - Adjusted research and development expenses decreased by 18% to $167 million [13] Guidance and Market Reaction - The company lowered its 2025 revenue guidance to $4.15-$4.30 billion, reflecting a $100 million cut at the upper end [10][14] - Adjusted earnings per share outlook was raised to $4.80-$5.60, up from the previous range of $4.00-$5.60 [10][18] - Shares of Jazz fell more than 7% in after-market trading following the earnings guidance and wider-than-expected loss [15]

Core Insights - Jazz Pharmaceuticals reported revenue of $1.05 billion for the quarter ended June 2025, reflecting a year-over-year increase of 2.1% but a slight miss of 0.26% against the Zacks Consensus Estimate [1] - The company experienced a significant decline in EPS, reporting -$8.25 compared to $5.30 in the same quarter last year, resulting in an EPS surprise of -34.8% against the consensus estimate of -$6.12 [1] Revenue Breakdown - Total revenues from royalties and contract revenues were $60.14 million, exceeding the average estimate of $55.53 million by analysts [4] - Product sales, net, amounted to $985.57 million, slightly below the average estimate of $999.45 million, with a year-over-year change of +2.2% [4] - Neuroscience total revenues reached $707.02 million, which was lower than the estimated $716.27 million, but represented a year-over-year increase of +3.3% [4] - Oncology total revenues were $274.15 million, marginally below the average estimate of $274.32 million, reflecting a year-over-year decrease of -1.1% [4] - Specific product performance included: - Rylaze/Enrylaze: $100.66 million, below the estimate of $105.31 million, a -6.7% change year-over-year [4] - Oxybate (Xywav & Xyrem): $450.67 million, exceeding the estimate of $440.11 million, with a +4.7% change year-over-year [4] - Sativex: $4.62 million, below the estimate of $5.63 million, a -27.7% change year-over-year [4] - Oxybate - Xyrem: $35.35 million, slightly above the estimate of $34.64 million, a -43.2% change year-over-year [4] - Defitelio/defibrotide: $48.11 million, above the estimate of $47.83 million, a +5.9% change year-over-year [4] - Vyxeos: $44.85 million, exceeding the estimate of $41.48 million, a +4.3% change year-over-year [4] - Zepzelca: $74.54 million, below the estimate of $77.82 million, an -8% change year-over-year [4] - Oxybate - Xywav: $415.32 million, above the estimate of $405.49 million, a +12.7% change year-over-year [4] Stock Performance - Jazz Pharmaceuticals' shares have returned +7.9% over the past month, outperforming the Zacks S&P 500 composite, which changed by +1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Jazz Pharmaceuticals reported disappointing first-quarter 2025 earnings, significantly missing consensus estimates due to increased operating expenses and a decline in revenues, leading to a drop in share price [1][2][4]. Financial Performance - Adjusted earnings for Q1 2025 were $1.68 per share, missing the Zacks Consensus Estimate of $4.51, representing a 36% year-over-year decline [1]. - Total revenues decreased by 0.5% year over year to $897.8 million, also falling short of the Zacks Consensus Estimate of $981 million [2]. - Net product sales remained flat at $839.4 million, missing both the Zacks Consensus Estimate and internal estimates [4]. Segment Performance - Neuroscience segment sales increased by 4% to $605.2 million, with combined oxybate sales (Xyrem + Xywav) rising about 1% to $382 million, but still missing estimates [6][7]. - Sales of Xyrem plummeted 42% year over year to $37.2 million due to patient transitions to Xywav and the introduction of authorized generics [6]. - Xywav sales reached $344.8 million, up 9% year over year, driven by strong uptake in narcolepsy and idiopathic hypersomnia indications [7]. - Oncology segment sales fell by 11% to $229.4 million, with specific drugs like Rylaze and Zepzelca experiencing significant declines due to competitive pressures and protocol updates [9][10][11]. Operating Costs - Adjusted selling, general and administrative expenses surged by 52% year over year to $472.3 million, primarily due to antitrust litigation settlements [13]. - Adjusted research and development expenses decreased by 22% to $220.9 million, attributed to lower clinical program costs [13]. Guidance and Outlook - Jazz Pharmaceuticals maintained its total sales guidance for 2025, projecting revenues between $4.15 billion and $4.40 billion, indicating a 5% year-over-year growth at the midpoint [15]. - Adjusted SG&A expenses are now expected to be between $1.47 billion and $1.53 billion, while adjusted R&D expenses are forecasted to be between $760 million and $810 million [16]. - The company revised its adjusted earnings guidance down to a range of $4.00 to $5.60 per share, significantly lower than previous estimates [16].